Free Trial
NASDAQ:DCOY

Decoy Therapeutics Q1 2026 Earnings Results & Report

Decoy Therapeutics logo
$1.06 -0.04 (-3.21%)
Closing price 03:50 PM Eastern
Extended Trading
$1.06 +0.01 (+0.47%)
As of 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Decoy Therapeutics reported Q1 2026 earnings on May 8, 2026. The company reported EPS of -$4.18.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes

Decoy Therapeutics EPS Results

Actual EPS
-$4.18
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Decoy Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Decoy Therapeutics Q1 2026 Earnings FAQ

Decoy Therapeutics (NASDAQ:DCOY) reported earnings of -$4.18 per share for Q1 2026. The report was announced on Friday, May 8, 2026.

Decoy Therapeutics Earnings Headlines

I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
See More Decoy Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Decoy Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Decoy Therapeutics and other key companies, straight to your email.

About Decoy Therapeutics

Decoy Therapeutics (NASDAQ:DCOY) is a biotechnology company developing messenger RNA (mRNA)-based medicines. Its technology is intended to direct the body’s cells to produce therapeutic proteins, with the goal of addressing diseases through targeted biological mechanisms.

The company’s research activities focus on applying its mRNA platform to potential treatments in areas including infectious disease and oncology. Its pipeline remains centered on investigational programs, and the company’s products are subject to the development, testing and regulatory approval processes required for biotechnology therapies.

Publicly available information about Decoy Therapeutics’ operating history, geographic presence and leadership is limited. Additional details may become available as the company advances its development programs and provides further corporate disclosures.

View Decoy Therapeutics Profile